Buy Insulent Corp. (PODD) on Weakness - Canaccord Genuity

Article Stock Quotes (1) Comments (0)

Today Canaccord Genuity reiterated their Buy rating on Insulet Corporation (NASDAQ: PODD) but cut the price target to $24.50 (from $27.00).

"Strength in the core OmniPod business was very encouraging, but offset by weaker-than-expected results from NDI," said William J. Plovanic.

"Given the continued back-and-forth with the FDA, we are now modeling for Gen2 to gain FDA clearance by YE/12, pushing out an acceleration in growth and margin improvement into the Q2/13," he added.

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $18.72 yesterday, with a 52 week range of $14.00-$21.92.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
• Wedbush Expects Positive Results from Insmed (INSM) ARIKAC Trial
• Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?